Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment

Largest Real-World Study of Patient-Reported Outcomes in People with Migraine Shows the Use of Novel CGRP Monoclonal Antibody Class May Improve Migraine INDIANAPOLIS, Oct. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Nearly 80% of people taking... Biopharmaceuticals, Neurology Eli Lilly, CGRP mAbs, migraine, OVERCOME study
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news